ALKS GoodMoat Verdict
Full signal breakdown coming soon. Use the X-Ray tool for a detailed analysis.
Alkermes plc
Exchange: NASDAQSector: HealthcareIndustry: Drug Manufacturers - Specialty & Generic
Alkermes plc, a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio.
Current Price
$37.48
-2.29%GoodMoat Value
$101.41
170.6% undervaluedProfile
Valuation (TTM)
Market Cap$6.25B
P/E40.90
EV—
P/B3.43
Shares Out166.65M
P/Sales4.00
Revenue$1.56B
EV/EBITDA26.47
Alkermes plc (ALKS) Quality Analysis
ALKS Profitability
Profitability trend analysis coming soon
ALKS Growth
Growth trend analysis coming soon
ALKS Financial Health
Financial health indicators coming soon
ALKS Quality & Fundamental Analysis
Alkermes plc (ALKS) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry, listed on NASDAQ. This quality analysis page evaluates Alkermes plc's financial health using the Piotroski F-Score methodology, profitability ratios, growth trajectory, and balance sheet strength.
Alkermes plc has a Piotroski F-Score of N/A out of 9, measuring profitability, leverage, and operating efficiency. The company operates with a profit margin of 9.78% and a return on equity (ROE) of 8.39%. Return on assets (ROA) stands at 6.14%.
The debt-to-equity ratio is 0.04, with a current ratio of 3.55. Operating margin is 17.21%.
GoodMoat's quality analysis uses AI-powered insights to evaluate whether Alkermes plc is a fundamentally sound investment. The GoodMoat Verdict synthesizes profitability, growth, and financial health scores into a clear investment quality rating. Use these metrics alongside valuation tools like the DCF calculator and fair value models to make informed investment decisions.